Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Refractory hairy cell leukemia"'
Autor:
Valentina Pettirossi, Alessandra Pucciarini, Enrico Tiacci, Stefano Volpetti, Alessia Santi, Mara Merluzzi, Vincenzo Perriello, Alessandra Venanzi, Edoardo Simonetti, Antonio Bennati, Brunangelo Falini, Gianluca Schiavoni, Stefano Ascani, Luca De Carolis, Luisa Tasselli
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc552a772c5c146306357086af3b3837
https://pubmed.ncbi.nlm.nih.gov/33731847
https://pubmed.ncbi.nlm.nih.gov/33731847
Publikováno v:
Annals of Hematology. 98:2443-2445
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0282a3924480e3eb9208ae2d4e5b32b9
https://doi.org/10.1007/s00277-019-03780-1
https://doi.org/10.1007/s00277-019-03780-1
Autor:
Robert J. Kreitman, Julie Feurtado
BACKGROUND: Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited. OBJECTIVES: To describe the authors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f481dfc54d6042a7f6a3eced2be60e1
https://europepmc.org/articles/PMC6688475/
https://europepmc.org/articles/PMC6688475/
Autor:
Samantha Ferrari, Enrico Tiacci, Natalia Frattarelli, L. De Carolis, Brunangelo Falini, Monia Capponi, Paolo Falcucci, R. Della Seta, Eugenio Lucia, A. Ambrosetti, Giuseppe Visani, G. Gaidano, Edoardo Simonetti, Alessandro Pulsoni, Robert Foa, Francesco Zaja, L. Rigacci, Agostino Antolino, P. L. Zinzani
Publikováno v:
HemaSphere. 3:3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70f35b6d20fa6942aa6fb492f21d8595
https://doi.org/10.1097/01.hs9.0000558636.55215.ad
https://doi.org/10.1097/01.hs9.0000558636.55215.ad
Autor:
Michael R. Grever
Publikováno v:
Blood. 127(23)
In this issue of Blood , Dietrich et al report that the low-dose BRAF inhibitor, vemurafenib, is highly effective in refractory hairy cell leukemia. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d643e57bd282e4bcfbcc40e951a531a1
https://pubmed.ncbi.nlm.nih.gov/26941398
https://pubmed.ncbi.nlm.nih.gov/26941398
Autor:
Robert J. Kreitman, Nathan Standifer, G. Saglio, Bjørn Tore Gjertsen, Pier Luigi Zinzani, Phillipp D. Le Coutre, Xavier Troussard, Gail J. Roboz, Claire Dearden, Wyndham H. Wilson, Francis J. Giles, Kemal Balic, Douglas E. Gladstone, Lionel Karlin, Peng He, Shannon Marshall, Nai-Shun Yao, Julio Delgado, Tadeusz Robak, Ira Pastan
Publikováno v:
Journal of Clinical Oncology. 36:7004-7004
7004Background: A pivotal multicenter, single-arm study evaluated moxetumomab pasudotox, a first-in-class recombinant immunotoxin, in patients (pts) with relapsed/refractory hairy cell leukemia (HC...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c847b9e5f9046de81df5342dcd836e20
https://doi.org/10.1200/jco.2018.36.15_suppl.7004
https://doi.org/10.1200/jco.2018.36.15_suppl.7004
Publikováno v:
American Journal of Hematology. 92:1398-1399
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::683a3ee35194b9e769b47df346cb6129
https://doi.org/10.1002/ajh.24580
https://doi.org/10.1002/ajh.24580
Autor:
Thorsten Zenz, Anthony D. Ho, Sascha Dietrich, Christof von Kalle, Mindaugas Andrulis, Hanno Glimm
Publikováno v:
New England Journal of Medicine. 366:2038-2040
The authors report a dramatic response to vemurafenib in a patient with hairy-cell leukemia refractory to nucleosides and rituximab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::279f5859853dd6c766848973ebc0fdc5
https://doi.org/10.1056/nejmc1202124
https://doi.org/10.1056/nejmc1202124
Autor:
Rie Ohtsuka, Yasunobu Abe, Ryoichi Takayanagi, Eriko Sada, Kensaku Idutsu, Motoaki Shiratsuchi, Eriko Nagasawa, Junichi Kiyasu
Publikováno v:
International Journal of Hematology. 89:403-405
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84403becf0a654d91da0f02e968ceca1
https://doi.org/10.1007/s12185-009-0297-2
https://doi.org/10.1007/s12185-009-0297-2
Autor:
Robert J. Kreitman, Hong Zhou, Wyndham H. Wilson, Mauricio Burotto, Evgeny Arons, Maryalice Stetler-Stevenson
Purpose: To determine tolerability and for the first time explore efficacy of bendamustine–rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using two different dose levels of bendamustine. Experimental Design: Patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca9d242bd8b1f9bcb059c880c9fb7f9
https://europepmc.org/articles/PMC3861900/
https://europepmc.org/articles/PMC3861900/